Inmode Ltd

Inmode Ltd(INMD)股票分析

$13.970

-0.080 (-0.57%)收盤時

Loading chart…
最高
14.050
開盤
14.000
成交量加權均價
13.98
成交量
420.69K
市值
1.53B
最低
13.920
成交金額
5.88M
企業價值/稅息折舊攤銷前利潤(TTM)
8.44

Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.

AI 分析 of Inmode Ltd (INMD)

持有

InMode Ltd is currently a hold. The stock is priced at $14.16, which is below the analyst price target of $17, indicating potential upside. However, the RSI is at 41.68, suggesting the stock is nearing oversold territory but not yet a strong buy signal. Additionally, the forward P/E ratio of 9.99 indicates it is undervalued compared to the market, but the recent 1-year change of -11.56% raises concerns about its performance. The main risk is the ongoing evaluation of the acquisition bid, which could lead to volatility in the stock price.

估值指標

Inmode Ltd(INMD)目前預期本益比為 9.99,5 年平均預期本益比為 12.26。

預期本益比

合理
5 年均值 P/E
12.26
目前P/E
9.99
高估
18.59
低估
5.93

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
8.46
目前EV/EBITDA
8.44
高估
13.67
低估
3.26

預期股價營收比

合理
5 年均值 P/S
4.44
目前P/S
2.13
高估
7.10
低估
1.79

Alphio AI 對 INMD 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%INMD

$15.83

情境價格

基

基準

基準 · 50%INMD

$13.90

情境價格

悲

悲觀

悲觀 · 25%INMD

$12.59

情境價格

持有 INMD 的大戶

H

Harel Insurance Investments & Financial Services Ltd

+ 持有INMD

+3.48%

3個月報酬率

M

Meitav Investment House Ltd

+ 持有INMD

-1.38%

3個月報酬率

事件時間軸

2026-10-19 (ET)

08:30:00

Steel Partners Proposes to Acquire InMode at $16.75 per Share

2026-10-13 (ET)

07:30:00

InMode Finalizing Q3 2026 Financial Results

2026-10-12 (ET)

09:00:00

Applix Inc. Borrow Rate Increases to 12.22%

2026-08-05 (ET)

08:00:00

Sees FY26 Revenue of $365M-$375M

2026-07-10 (ET)

07:30:00

InMode Receives Acquisition Proposal from Steel Partners

資訊

INMD 常見問題 —— 由 Alphio AI 解答

Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures. It operates in the Healthcare sector (ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS industry).

InMode Ltd is currently a hold. The stock is priced at $14.16, which is below the analyst price target of $17, indicating potential upside. However, the RSI is at 41.68, suggesting the stock is nearing oversold territory but not yet a strong buy signal. Additionally, the forward P/E ratio of 9.99 indicates it is undervalued compared to the market, but the recent 1-year change of -11.56% raises concerns about its performance. The main risk is the ongoing evaluation of the acquisition bid, which could lead to volatility in the stock price.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易